BIOLASE Reports 31% Sequential Revenue Growth In 2020 Fourth Quarter; Demand From New Users Driving Positive Performance

 

FOOTHILL RANCH, Calif., March 25, 2021 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced its financial results for the fourth quarter and full year ended December 31, 2020.

2020 Fourth Quarter Operating Highlights and Recent Developments:

  • Total revenue was $8.5 million, representing sequential quarterly growth of 31%.
  • U.S. revenue exceeded the prior-year fourth quarter, despite COVID-19 headwinds.
  • 78% of sales came from new users, continuing a positive trend.
  • 40% of sales came from dental specialists, a significant increase compared to recent prior periods.
  • Several Dental Services Organizations ("DSOs") purchased BIOLASE products in the fourth quarter, including Heartland Dental, Dental Care Alliance, Aspen Dental and Virginia Family Dentistry.
  • BIOLASE significantly bolstered its balance sheet during the COVID-19 pandemic as cash and cash equivalents totaled $17.9 million on December 31, 2020.
  • The Company completed a $14.4 million bought deal in February 2021 increasing its current cash and cash equivalents to approximately $40.0 million as of February 28, 2021, including the proceeds from the exercise of warrants sold in the Company's July 2020 rights offering.

"Our strong fourth quarter revenue performance is our second consecutive quarter of significant sequential growth and was driven by sales to new customers, dental specialists and DSOs in the U.S.," commented John Beaver, President and Chief Executive Officer. "Dental specialists, such as endodontist and periodontists, comprised 40% of our U.S. laser sales in the fourth quarter, reflecting our ongoing efforts to educate and train these dental specialists on the benefits of our lasers to drive increased adoption. Our industry-leading dental lasers provide a new, improved and better standard of care for dental procedures while ensuring a safer environment for dental practitioners and patients by reducing aerosolization to mitigate the spread of infectious pathogens, such as COVID-19. We are experiencing high demand from dental specialists for our advanced dental lasers because these products provide the opportunity they seek for safer, more advanced alternatives to grow their practices.

"We have continued to make adjustments to our go-to-market approach during the pandemic, and the momentum we are seeing in the current 2021 first quarter gives us greater confidence that we are nearing a resumption of the growth we were generating prior to COVID-19. Specifically, despite the ongoing impact of the pandemic, we expect to report total revenue growth of approximately 65% for the current first quarter compared to the same quarter a year ago."  

2020 Fourth Quarter Financial Results

Net revenue for the fourth quarter of 2020 was $8.5 million, an increase of 31% sequentially from third quarter revenue of $6.5 million. Compared to the year-ago fourth quarter, which was the last full quarter prior to the impact of the COVID-19 pandemic, revenue decreased 17% from $10.2 million. U.S. laser revenue was $3.8 million for the fourth quarter of 2020, up 15% when compared to U.S. laser revenue of $3.3 million for the fourth quarter of 2019. U.S. consumables and other revenue for the fourth quarter of 2020, which consists of revenue from consumable products such as disposable tips, decreased 10% compared to the fourth quarter of 2019. Outside the U.S., laser revenue declined 52% to $1.7 million for the fourth quarter of 2020 compared to $3.5 million for the fourth quarter of 2019, and consumables and other revenue decreased 13% year over year as recovery from the pandemic has come slower internationally.

Gross margin for the fourth quarter of 2020 was 19%, compared to 43% for the fourth quarter of 2019. The lower gross margin reflects the impact of a decline in revenues relative to our fixed costs and a $1.0 million expense for inventory obsolescence. These impacts were partially offset by higher average U.S. selling prices of our lasers. Total operating expenses were $7.1 million for the fourth quarter of 2020 compared to $7.5 million for the fourth quarter of 2019, a decrease of approximately 5%. Operating loss for the fourth quarter of 2020, was $5.5 million, compared to an operating loss of $3.0 million in the fourth quarter of 2019. Net loss for the fourth quarter of 2020 was $6.1 million, or $0.07 per share, compared to a net loss of $3.6 million, or $0.13 per share, for the fourth quarter of 2019.

Full Year 2020 Financial Results

Net revenue for the year ended December 31, 2020 was $22.8 million, a decrease of 40% compared to net revenue of $37.8 million for the year ended December 31, 2019. U.S. laser revenue was $8.3 million for the year ended December 31, 2020, a decrease of 25% compared to U.S. laser revenue of $11.1 million for the year ended December 31, 2019. U.S. consumables and other revenue for the year ended December 31, 2020, which consists of revenue from consumable products such as disposable tips, decreased 29% year over year. International laser revenue decreased to $4.0 million for the year ended December 31, 2020 compared to $11.7 million for the year ended December 31, 2019.

Gross margin for the year ended December 31, 2020 was 27% compared to 38% for the year ended December 31, 2019. Total operating expenses were $24.7 million for the year ended December 31, 2020 compared to $29.9 million for the year ended December 31, 2019, a decrease of $5.2 million, or 17%, year over year. Operating loss for the year ended December 31, 2020 was $18.5 million, compared to an operating loss of $15.6 million for the year ended December 31, 2019, an increase of $2.9 million year over year. Net loss for the year ended December 31, 2020 was $16.8 million, or $0.28 per share, compared to a net loss of $17.9 million, or $0.77 per share, for the year ended December 31, 2019.

Adjusted EBITDA – Use of Non-GAAP Measures

The Reconciliation of GAAP Net Loss to Adjusted EBITDA at the end of this news release provides the details of the Company's non-GAAP disclosures and the reconciliation of GAAP net loss and net loss per share to the Company's Adjusted EBITDA and Adjusted EBITDA per share.

Adjusted EBITDA loss for the fourth quarter of 2020 was $4.5 million, or $0.05 per share, compared with Adjusted EBITDA loss of $1.7 million, or $0.05 per share, for the fourth quarter of 2019.

Adjusted EBITDA for the year ended December 31, 2020 was a loss of $13.4 million, or $0.22 per share, compared with an Adjusted EBITDA loss of $10.3 million, or $0.45 per share, for the year ended December 31, 2019.

2021 First Quarter Revenue Guidance

For the first quarter ending March 31, 2021, the Company expects total revenue of $7.5 million to $8.0 million, which would represent growth between 60% and 70% year over year.

Conference Call Information

BIOLASE, Inc. will host a conference call today at 4:30 p.m. Eastern Time to discuss its operating results for the fourth quarter and full year ended December 31, 2020, and to answer questions. For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the U.S./Canada is 800-353-6461. For international participants outside the U.S./Canada, the dial-in number is 334-323-0501. For all callers, refer to the Conference ID 7623727. To access the live webcast, visit the Investor Relations section of the BIOLASE website at www.biolase.com and see "Investor Events".

An audio archive of the webcast will be available for 30 days on the Investor Relations section of the BIOLASE website.

About BIOLASE

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE's proprietary laser products incorporate approximately 271 patented and 40 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. BIOLASE has sold over 41,200 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.

BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements, regarding BIOLASE's expected revenue and revenue growth during the first quarter of 2021. Forward-looking statements can be identified through the use of words such as may," "might," "will," "intend," "should," "could," "can," "would," "continue," "expect," "believe," "anticipate," "estimate," "predict," "outlook," "potential," "plan," "seek," and similar expressions and variations or the negatives of these terms or other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors. These factors include, among others, the coronavirus (COVID-19) and the effects of the outbreak and actions taken in connection therewith, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that are described in the "Risk Factors" section of BIOLASE's most recent annual report filed on Form 10-K and quarterly report filed on Form 10-Q filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.

Tables to Follow

BIOLASE, INC.

 

CONSOLIDATED STATEMENTS OF OPERATIONS

 

(Unaudited)

 

(In thousands, except per share data)

 
                                         
   

Three Months Ended

   

Twelve Months Ended

 
   

December 31,

   

December 31,

 
   

2020

   

2019

   

2020

   

2019

 

Net revenue

 

$

 

8,520

   

$

 

10,182

   

$

 

22,780

   

$

 

37,799

 

Cost of revenue

     

6,915

       

5,765

       

16,607

       

23,511

 

Gross profit

     

1,605

       

4,417

       

6,173

       

14,288

 

Operating expenses:

                                       

Sales and marketing

     

3,767

       

3,731

       

11,242

       

14,396

 

General and administrative

     

2,326

       

2,634

       

9,772

       

10,748

 

Engineering and development

     

1,051

       

1,100

       

3,695

       

4,765

 

Total operating expenses

     

7,144

       

7,465

       

24,709

       

29,909

 

Loss from operations

     

(5,539)

       

(3,048)

       

(18,536)

       

(15,621)

 

(Gain) loss on foreign currency transactions

     

(47)

       

53

       

21

       

121

 

Interest expense, net

     

577

       

598

       

2,359

       

2,157

 

Other (income) expense, net

     

(6)

       

       

(4,215)

       

 

Non-operating (loss) gain

     

524

       

651

       

(1,835)

       

2,278

 

Loss before income tax provision

     

(6,063)

       

(3,699)

       

(16,701)

       

(17,899)

 

Income tax provision (benefit)

     

79

       

(112)

       

128

       

(44)

 

Net loss

 

$

 

(6,142)

   

$

 

(3,587)

   

$

 

(16,829)

   

$

 

(17,855)

 
                                         

Net loss

 

$

 

(6,142)

   

$

 

(3,587)

   

$

 

(16,829)

   

$

 

(17,855)

 

Deemed dividend on convertible preferred stock

     

       

       

(17,378)

       

 

Net loss attributable to common stockholders

 

$

 

(6,142)

   

$

 

(3,587)

   

$

 

(34,207)

   

$

 

(17,855)

 
                                         

Net loss per share attributable to common stockholders:

                                       

Basic

 

$

 

(0.07)

   

$

 

(0.13)

   

$

 

(0.56)

   

$

 

(0.77)

 

Diluted

 

$

 

(0.07)

   

$

 

(0.13)

   

$

 

(0.56)

   

$

 

(0.77)

 

Shares used in the calculation of net loss per share:

                                       

Basic

     

93,211

       

28,118

       

61,136

       

23,201

 

Diluted

     

93,211

       

28,118

       

61,136

       

23,201

 

 

BIOLASE, INC.

 

CONSOLIDATED BALANCE SHEETS

 

(In thousands, except per share data)

 
                     
   

December 31,

   

December 31,

 
   

2020

   

2019

 
   

(Unaudited)

   

(Audited)

 

ASSETS

                   

Current assets:

                   

Cash and cash equivalents

 

$

 

17,564

   

$

 

5,789

 

Restricted cash

     

312

       

312

 

Accounts receivable, less allowance of $4,017 and $2,531 in 2020 and 2019, respectively

     

3,059

       

8,760

 

Inventory

     

11,157

       

10,995

 

Prepaid expenses and other current assets

     

3,018

       

1,163

 

Total current assets

     

35,110

       

27,019

 

Property, plant and equipment, net

     

782

       

1,193

 

Goodwill

     

2,926

       

2,926

 

Right of use asset

     

1,976

       

276

 

Other assets

     

231

       

433

 

Total assets

 

$

 

41,025

   

$

 

31,847

 
                     

LIABILITIES, REDEEMABLE PREFERRED STOCK AND

STOCKHOLDERS' EQUITY

               

Current liabilities:

                   

Accounts payable

 

$

 

2,651

   

$

 

5,332

 

Accrued liabilities

     

6,667

       

4,744

 

Deferred revenue, current portion

     

1,905

       

2,237

 

Total current liabilities

     

11,223

       

12,313

 

Deferred revenue

     

374

       

358

 

Warranty accrual

     

384

       

245

 

Non current term loans, net of discount

     

16,186

       

13,466

 

Non current operating lease liability

     

1,774

       

4

 

Other liabilities

     

1,056

       

1,119

 

Total liabilities

     

30,997

       

27,505

 

Redeemable preferred stock:

                   

Series E Preferred stock, par value $0.001 per share

     

       

3,965

 

Total redeemable preferred stock

     

       

3,965

 

Stockholders' equity:

                   

Series F Preferred stock, par value $0.001 per share

     

118

       

 

Common stock, par value $0.001 per share

     

98

       

31

 

Additional paid-in capital

     

261,573

       

235,594

 

Accumulated other comprehensive loss

     

(385)

       

(701)

 

Accumulated deficit

     

(251,376)

       

(234,547)

 

Total stockholders' equity

     

10,028

       

377

 

Total liabilities, redeemable preferred stock and stockholders' equity

 

$

 

41,025

   

$

 

31,847

 

 

BIOLASE, INC.

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

(Unaudited, in thousands)

 
   

Twelve Months Ended

 
   

December 31,

 
   

2020

       

2019

 

Cash Flows from Operating Activities:

                   

Net loss

 

$

(16,829)

       

$

(17,855)

 

Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:

                   

  Depreciation and amortization

   

499

         

982

 

  Provision for bad debts

   

1,328

         

1,695

 

  Provision for sales returns

   

87

         

 

  Provision for inventory excess and obsolescence

   

(591)

         

413

 

  Inventory disposals

   

1,300

         

15

 

  Amortization of discounts on lines of credit

   

165

         

140

 

  Amortization of debt issuance costs

   

331

         

188

 

  Change in fair value of warrants

   

(5,850)

         

 

  Issuance costs for common stock warrants

   

1,641

         

 

  Stock-based compensation

   

3,370

         

2,742

 

  Warrants issued to consultants

   

         

48

 

  Deferred income taxes

   

         

7

 

  Earned interest income

   

         

2

 

  Changes in operating assets and liabilities:

                   

  Accounts receivable

   

4,286

         

655

 

  Inventory

   

(871)

         

825

 

  Prepaid expenses and other current assets

   

825

         

439

 

  Accounts payable and accrued liabilities

   

(2,107)

         

(3,156)

 

  Deferred revenue

   

(379)

         

114

 

Net cash and cash equivalents used in operating activities

   

(12,795)

         

(12,746)

 

Cash Flows from Investing Activities:

                   

 Purchases of property, plant, and equipment

   

(96)

         

(207)

 

Net cash and cash equivalents used in investing activities

   

(96)

         

(207)

 

Cash Flows from Financing Activities:

                   

  Proceeds from the issuance of common stock

   

6,912

         

9,171

 

  Proceeds from the issuance of Series F Convertible Preferred Stock

   

2,700

         

 

  Proceeds from the issuance of July 2020 Warrants

   

15,300

         

 

  Payments of equity offering costs

   

(1,281)

         

(821)

 

  Payments of warrant issuance costs

   

(1,640)

         

 

  Borrowings on other long-term loans

   

3,140

         

 

  Borrowings under term loan

   

         

2,500

 

  Principal payment on term loan

   

(700)

         

 

  Borrowings on credit facility

   

3,000

         

 

  Repayment of credit facility

   

(3,000)

         

 

  Payment of debt issuance costs

   

(128)

         

(133)

 

  Proceeds from the exercise of common stock warrants

   

46

         

 

  Proceeds from exercise of stock options

   

         

4

 

Net cash and cash equivalents provided by financing activities

   

24,349

         

10,721

 

  Effect of exchange rate changes

   

317

         

(23)

 

  Decrease in cash, cash equivalents and restricted cash

   

11,775

         

(2,255)

 

Cash, cash equivalents and restricted cash, beginning of period

   

6,101

         

8,356

 

Cash, cash equivalents and restricted cash, end of period

 

$

17,876

       

$

6,101

 

Supplemental cash flow disclosure:

                   

  Cash paid for interest

 

$

1,881

       

$

1,784

 

  Cash received for interest

 

$

11

       

$

 

  Cash paid for income taxes

 

$

22

       

$

35

 

  Cash paid for operating leases

 

$

489

       

$

797

 

  Non-cash accrual for capital expenditures

 

$

       

$

18

 

  Non-cash settlement of performance award liability

 

$

151

       

$

201

 

  Non-cash right-of-use assets obtained in exchange for lease obligation

 

$

2,037

       

$

276

 

  Equity financing costs in accounts payable

 

$

74

       

$

129

 

  Deemed dividend on convertible preferred stock

 

$

17,378

       

$

 

  Forgiveness of debt

 

$

10

       

$

 

  Warrants exercised in other receivables

 

$

1,498

       

$

 

  Warrants issued in connection with debt instruments

 

$

67

       

$

161

 

Non-GAAP Disclosure

In addition to the financial information prepared in conformity with generally accepted accounting principles in the U.S. ("GAAP"), this press release includes certain historical non-GAAP financial information. Management believes that these non-GAAP financial measures assist investors in making comparisons of period-to-period operating results and that, in some respects, these non-GAAP financial measures are more indicative of the Company's ongoing core operating performance than their GAAP equivalents. In 2019, the Company revised its non-GAAP financial measures to include the change in allowance for doubtful accounts in an effort to better align its Adjusted EBITDA with its loan covenants and how management evaluates business performance.

Adjusted EBITDA is defined as net income (loss) before interest, taxes, depreciation and amortization, stock-based compensation, and allowance for doubtful accounts. Management uses Adjusted EBITDA in its evaluation of the Company's core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the Company may be different from similarly named non-GAAP financial measures used by other companies.

BIOLASE, INC.

 

Reconciliation of GAAP Net Loss to Adjusted EBITDA

 

(Unaudited)

 

(In thousands, except per share data)

 
                         
 

Three Months Ended

   

Twelve Months Ended

 
 

December 31,

   

December 31,

 
 

2020

   

2019

   

2020

   

2019

 

GAAP net loss attributable to common stockholders

$

 

(6,142)

   

$

 

(3,587)

   

$

 

(34,207)

   

$

 

(17,855)

 

Deemed dividend on convertible preferred stock

   

       

       

17,378

       

 

GAAP net income (loss)

$

 

(6,142)

   

$

 

(3,587)

   

$

 

(16,829)

   

$

 

(17,855)

 

Adjustments:

                                     

Interest expense, net

   

577

       

598

       

2,359

       

2,157

 

Income tax (benefit) provision

   

79

       

(112)

       

128

       

(44)

 

Depreciation and amortization

   

(28)

       

228

       

499

       

982

 

Change in allowance for doubtful accounts

   

65

       

452

       

1,328

       

1,695

 

Stock-based compensation

   

1,003

       

768

       

3,370

       

2,742

 

Other (income) expense, net

   

(6)

       

       

(4,215)

       

 

Adjusted EBITDA

$

 

(4,452)

   

$

 

(1,653)

   

$

 

(13,360)

   

$

 

(10,323)

 
                                       

GAAP net loss attributable to common stockholders per share, basic and diluted

$

 

(0.07)

   

$

 

(0.13)

   

$

 

(0.56)

   

$

 

(0.77)

 

Deemed dividend on convertible preferred stock

   

       

       

0.28

       

 

GAAP net income (loss) per share, basic and diluted

$

 

(0.07)

   

$

 

(0.13)

   

$

 

(0.28)

   

$

 

(0.77)

 

Adjustments:

                                     

Interest expense, net

   

0.01

       

0.02

       

0.04

       

0.09

 

Income tax (benefit) provision

   

       

       

       

 

Depreciation and amortization

   

       

0.01

       

0.01

       

0.04

 

Change in allowance for doubtful accounts

   

       

0.02

       

0.02

       

0.07

 

Stock-based compensation

   

0.01

       

0.03

       

0.06

       

0.12

 

Other (income) expense, net

   

       

       

(0.07)

       

 

Adjusted EBITDA per share, basic and diluted

$

 

(0.05)

   

$

 

(0.05)

   

$

 

(0.22)

   

$

 

(0.45)

 

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/biolase-reports-31-sequential-revenue-growth-in-2020-fourth-quarter-demand-from-new-users-driving-positive-performance-301256277.html

SOURCE BIOLASE, Inc.

 
 
Company Codes: NASDAQ-SMALL:BIOL
 

Back to news